Clinical Outcome of Extended Curettage with Postoperative Denosumab Administration for the Treatment of Campanacci Grade III Giant Cell Tumors of the Extremities
Shuai Zhang, JiaQi Zhao, Lei Song · 2024
Read Clinical Outcome of Extended Curettage with Postoperative Denosumab Administration for the Treatment of Campanacci Grade III Giant Cell Tumors of the Extremities by Shuai Zhang, JiaQi Zhao, Lei Song (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11662700.txt.
Description
Shuai Zhang, Jiaqi Zhao, and Lei Song report what came of a joint-sparing surgery plus a bone drug for the worst grade of giant cell tumor in limbs. Their 2024 study covers a tumor that eats bone near joints. The team scraped the tumor out widely, then gave the drug denosumab after surgery, with none before it.
They tracked 23 patients treated from 2017 to 2023, for about three years on average. All cuts healed cleanly, with no deep infection or hardware failure. Three patients saw the tumor come back in place, a rate of thirteen percent. Two of those were fixed with a repeat scrape and stayed clear for two years. One needed the bone cut out and rebuilt with a living graft. One patient got knee arthritis.
Catalog record
| CREATOR | Shuai Zhang, JiaQi Zhao, Lei Song |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |